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Myasthenia gravis and pregnancy
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Myasthenia gravis (MG) is an autoimmune disorder with bimodal age of presentation,
occurring in young women of reproductive age and at an older age in men. Occasionally,
MG is diagnosed during pregnancy. Management of MG includes symptomatic treatment with cholinesterase inhibitors and immunosuppressive therapy for controlling the
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disease activity. Treatment of MG in women of reproductive age, who may be contemplating pregnancy, requires discussion regarding the choice of medication as well as the
understanding of risks/adverse effects involved with various treatments. During the
peripartum period, it is essential to ensure careful monitoring of the disease state along
with the well-being of the mother and fetus and to coordinate neonatal monitoring
overseen by a multidisciplinary team comprising a high-risk maternal fetal medicine specialist, a neurologist familiar with these complex issues, and a neonatologist.
KEYWORDS

immunosuppressive medications, myasthenia gravis, neonatal, pregnancy, teratogenic

1

|

I N T RO DU CT I O N
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I M P A C T O F P R E G N A N C Y ON M G

Myasthenia gravis (MG) is a chronic autoimmune disorder presenting

The clinical course of MG during pregnancy varies from one patient to

with fatigable weakness of the skeletal muscles. The reported esti-

another and even between pregnancies in the same patient. Different

mated prevalence of MG in the general population varies greatly,

studies report varying effects of pregnancy on MG; 19%–50% will

1

ranging from 15 to 179 per 1 000 000. The estimated incidence rates

experience worsening, 30%–59% will remain stable, and about 20%

range from 1.7 to 21.3 per 1 000 000, with bimodal distribution, the

will improve.3-5 A single observational study suggested possible pre-

first peak occurring in women in the third decade and then in men

dictors for the course of MG during pregnancy: the MG composite

over 60 y of age.1 Early onset MG (prior to age 40 y) is three times

score (MGC), duration of MG prior to pregnancy, and results of repeti-

2

more prevalent in women than men. This age of increased MG preva-

tive nerve stimulation (RNS).3 In this study, worsening was seen in

lence overlaps with the time for child bearing. When treating a patient

patients who had abnormal RNS results. Interestingly, a lower MGC

in the child-bearing age range, who may over time contemplate

score was associated with worsening and a higher MGC score with

getting pregnant, one must consider a medication that would not

improvement during pregnancy. The group that remained stable had

reduce fertility or harm the development of the fetus. Before initiating

longer disease duration and normal RNS testing prior to pregnancy.3

any such treatment in patients in this age range, pregnancy status

However, no similar correlation between prior MG status and exacer-

should be elicited. Selection of the appropriate treatment option

bation during pregnancy was found by Batocchi and colleagues.4

requires balancing the risk of exposure to the fetus vs the risk of MG

Exacerbations of symptoms mostly occur in the first or second

worsening/crisis.

trimesters or after delivery.3,4,6

3
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I M P A C T O F M G O N P RE G N A N C Y

MG is not known to affect pregnancy significantly. Some studies have
shown preterm premature rupture of membranes and increased

wileyonlinelibrary.com/journal/mus
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incidence of cesarean section due to uterine inertia, whereas other

Lack of adequate human studies limits the ability to provide recom-

studies did not show similar adverse effects on the course of preg-

mendations regarding use of rituximab or eculizumab when anticipating

nancy or mode of delivery.3-5,7-10 There are only 11 reported cases of

pregnancy. Animal studies in monkeys have not shown any evidence of

MG with severe preeclampsia reported thus far in the literature.11

teratogenicity with rituximab. B-cell lymphocytopenia has been reported

Although rare, this poses difficult management issues. Bone marrow

in infants exposed in-utero. Animal studies with mouse analogue of

suppression during pregnancy has been reported in an MG patient.12

eculizumab (murine anti C5-antibody) showed an increased rate of fetal

Higher maternal mortality is associated with shorter disease duration

loss, although no effect on fertility was noted. Continued use of rituximab

prior to pregnancy,8 and this could be due to less than full

and eculizumab as a maintenance treatment in MG should only be

optimization of MG treatment.

considered if the potential benefits clearly outweigh the risks to the fetus.

3.1

3.2

|

Pre-pregnancy counseling and medical care

|

Effect of medication on fertility

In an ideal situation in planning a pregnancy, no medications other

Of the maintenance medications for MG, pyridostigmine and cortico-

than prenatal vitamins should be taken; however; in MG patients

steroids do not have a negative impact on fertility.

continued symptomatic treatment and at times use of immunosuppressants is required.

AZA has not been shown to alter fertility in men or women. It is,
however, linked to mutagenesis in sperm. Based on this, for treated

Careful pregnancy planning is strongly recommended to optimize

males, it has been recommended that AZA be stopped 3 mo prior to

fetal health. Effective methods of contraception should be utilized when

conception (which is equivalent to one cycle of spermatogenesis); how-

not considering pregnancy to minimize the chances of exposure of the

ever, there are conflicting data that suggest it may be safe to continue

fetus to potentially deleterious medication in case of an unplanned preg-

AZA.16,20-22 If there is a question about starting AZA in the male part-

nancy. In addition to general nutritional advice and prenatal care, counsel-

ner of a couple contemplating pregnancy, referral to a geneticist and/or

ing includes evaluating medications for their effect on fertility and

sperm cryopreservation should be considered. Furthermore, ultrasound

stopping or switching maintenance MG medications that may have

survey of the fetus is recommended if conception is by a treated father.

adverse effects on the fetus. Since no set guidelines exist for optimum

No data are available on fertility in males treated with MMF. In

timing for discontinuing immunosuppressive medications prior to concep-

pregnancies fathered by patients treated with MMF, the rate of

tion, pharmacokinetics of the drug are used to determine that interval.

prematurity and malformations are similar to those seen in general

Pyridostigmine is completely safe during the time prior to concep8,13

tion and during pregnancy.

population.23 Female fertility has not been reported to be affected.

Prednisone is considered relatively safe

Methotrexate may have negative effects on spermatogenesis and is

as it does not pose significant risk to the mother or the fetus. It has

known to cause mutagenesis. This mutagenic effect reverses in about

been inconsistently reported to be associated with increased risk of

3 mo after discontinuation of treatment.24 In women, fertility is not

cleft lip/palate and use of lowest possible dose during pregnancy is

affected.

recommended.8,14,15

Cyclophosphamide has been shown to reduce ovarian reserve in

Medications that may be used with caution include azathioprine

a dose-dependent manner.25

(AZA) and anti-calcineurins. Use of AZA has not been associated with

Use of cyclosporine is not associated with reduction in female

reduced fertility or increased risk of congenital malformations.16 Intra-

fertility. Doses higher than 2 mg/kg/day in men can cause

uterine growth retardation has been reported, although it cannot be

asthenoteratospermia (malformed sperm with reduced motility); but no

solely attributed to the use of AZA. Its continued used should be

effect is reported in lower doses. Tacrolimus has not been reported to

weighed against the possibility of disease worsening and a negative

affect fertility. There is paucity of data on the effect of fertility with use

outcome secondary to that. Anti-calcineurins, including cyclosporine

of rituximab. Animal data suggest no effect on fertility with eculizumab.

and tacrolimus, can be continued with caution as no major
malformations are reported with either drug.
The medications that should be discontinued prior to conception,

3.3

|

Interaction with oral contraceptives

due to the teratogenic effect on the fetus, include mycophenolate
mofetil (MMF), methotrexate, and cyclophosphamide. MMF has a black

There are no reports linking MG medications to reduced efficacy of

box warning for use in women of child-bearing potential. It should be

oral contraceptives. Estrogen based contraceptives can increase the

17

discontinued at least 6 wk prior to conception.

Methotrexate can be

levels of tacrolimus, thus increasing the chances of toxicity.26

detected in red cells for up to 10 wk and in liver for about 4 mo after
discontinuation.18 It should be discontinued at least 3–4 mo prior to
planned conception as it has teratogenic effect on the fetus. Cyclophos-

3.4

|

Role of thymectomy

phamide use has been associated with increased rate of amenorrhea
and infertility.16,19 It is recommended that patients wait for 3 mo after

Thymectomy is a standard treatment offered to patients with acetyl-

discontinuation of cyclophosphamide before conception.16

choline receptor (AChR) antibody MG.27 Patients who have

3
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undergone thymectomy are less likely to have MG exacerbations

3.5.3

|

Azathioprine

during pregnancy as compared with mothers who have not had
thymectomy.28 Incidence of neonatal MG is also less in infants of

AZA has been used for a number of years in pregnant patients with

mothers who have had thymectomy.8 Thymectomy should be

various systemic autoimmune disorders and after solid organ trans-

considered in women prior to considering a future pregnancy.

plantation. AZA crosses the placenta, where it is metabolized to an
inactive metabolite, thiouric acid. The old FDA pregnancy classification assigned to AZA was category D; however, it has been success-

3.5

Medication use during pregnancy

|

fully used during pregnancy without significant issues. This older
classification has now been replaced by the PLLR system as men-

The medications typically used in patients with MG include

tioned above. Sporadic malformations including cardiac septal defects

pyridostigmine, prednisone, as well as agents broadly classified as ste-

have been reported, although a specific pattern of congenital mal-

roid sparing immunosuppressants such as AZA and MMF. Less com-

formations has not been seen.16 Increased risk of preterm delivery

monly used immunosuppressive medications in the United States

and low birth weight infants is seen in patients treated with AZA,

include methotrexate, tacrolimus, cyclosporine, cyclophosphamide,

although it remains unclear whether this is due to the drug or the

and rituximab. In the older system of drug classification by the Food

primary autoimmune disease itself. Various other studies report of use

and Drug Administration (FDA), most of the MG medications were

of AZA during pregnancy for other autoimmune disorders without

categorized as either Class C or D, with the exception of methotrex-

increased risk of congenital malformations.30,31

ate which was categorized as X. The old system, which assigned five
letter risk categories—A, B, C, D, or X—established in 1979, was felt
by clinicians to be overly simplistic and confusing. A new system,

3.5.4

|

MMF

pregnancy and lactation labeling final rule (PLLR), was adopted in
2015 and provides information about the risk to the fetus, registry

MMF is a reversible inhibitor of inosine phosphate dehydrogenase.

information, and safety during breast feeding as well as information

It readily crosses the placenta and is linked to an increased inci-

about effect on fertility and birth control. Prescription drugs submit-

dence of spontaneous abortions and congenital malformations. An

ted for FDA approval after June 30, 2015 use the PLLR labeling for-

embryopathy associated with the use of MMF affecting the ear,

mat, while drugs approved on or after June 2001 are being phased in

mouth, fingers, and organs (termed EMFO tetrad) has been

gradually to adopt the new format. Medications approved prior to

described. EMFO tetrad has demonstrated involvement in the fol-

2001 are not subject to the PLLR rule, however, are required to

lowing ways: ears, microtia and auditory canal atresia; mouth, cleft

remove the old pregnancy letter category. Table 1 includes recom-

lip and palate; fingers and toes, brachydactyly fifth fingers and

mendations for maintenance medications for MG patients regarding

hypoplastic toenails; and organs, cardiac, renal, central nervous sys-

their effects on fertility and pregnancy.

tem (CNS), diaphragm, and eyes.32,33 Due to these teratogenic
effects, the drug has a black box warning against its use in women
of child-bearing potential.

3.5.1

|

Pyridostigmine

Pyridostigmine has not been shown to cause teratogenicity in animal

3.5.5

|

Cyclophosphamide

models, and there are no adequate and well-controlled human studies.
This provides symptomatic relief, same as in non-pregnant MG

Cyclophosphamide has been shown to have a teratogenic effect on

patients. Maximum recommended dose for pyridostigmine is less than

the developing fetus. It is absolutely contraindicated in early preg-

600 mg/day.13 Intravenous cholinesterase inhibitors should be

nancy and is associated with severe embryopathy, including craniofa-

avoided as they can cause premature labor.15

cial abnormalities, developmental delay, and distal limb defects.34 Use
in the latter part of pregnancy is also associated with fetal harm and
should be taken with extreme caution.

3.5.2

|

Prednisone/prednisolone

Prednisone/prednisolone is often the sole immunosuppressant used

3.5.6

|

Methotrexate

through the course of pregnancy in patients with MG. Prednisone and
prednisolone are inactivated by the placenta, reducing the exposure

Methotrexate is contraindicated during pregnancy and lactation. In

to the fetus..29 Premature rupture of membranes and intrauterine

high doses, methotrexate works as an abortifacient. Its use at lower

growth retardation may occur.14,15 Cleft lip and palate have been

doses is also associated with significant fetal loss and fetal

inconsistently associated with maternal use of corticosteroids during

malformations.35 Aminopterin syndrome can occur, which is charac-

early pregnancy. Use of corticosteroids increases the risk for develop-

terized by CNS malformations, skull defects, facial and limb deformi-

ment of gestational diabetes and hypertension in the mother.16

ties, and cardiovascular abnormalities.36

Old FDA
pregnancy
classification

C

C

D

D

C

X

D

C

Pyridostigmine

Prednisone

Azathioprine

Mycophenolate

Cyclosporine/
tacrolimus

Methotrexate

Cyclophosphamide

Rituximab

No data available on effect
on fertility

Reduces ovarian reserve in
women which is dose
dependent

Men: Possible effect on
spermatogenesis, known
to have mutagenic effect
in spermwomen: No effect

Cyclosporine: Doses
>2 mg/kg/d can cause
asthenoteratospermia,no
effect on fertility in
womentacrolimus: No
effect in men or women

No effect on fertility in men
or women

No effect on fertility,
although has mutagenic
effect on sperm

Men: High doses can cause
mild suppression of
hypothalamic–pituitary–
gonadal axiswomen:
No effect

None in men or women

Effect on fertility

May be continued

Not recommended due
to lack of data

May be continued

Contraindicated

Contraindicated

Not recommended due
to lack of data

Increased risk of preterm
delivery

Contraindicated in pregnancy

May increase risk of preterm
labor

Contraindicated

Contraindicated

Limited data – although no
adverse effects reported

Low birth weight, sporadic
malformations such as
cardiac septal defects

Teratogenic: Black box
warning for use in
pregnancy, Embryopathy
(termed EMFO tetrad) has
been described
Low birth weight, transient
neonatal hyperkalemia,
and renal impairment—
Resolve spontaneously

Teratogenic: Causes CNS,
skull, facial, and limb
abnormalities

B-cell lymphocytopenia may
occur, typically recovering
within 6 mo of birth

Teratogenic: Severe
embryopathy including
craniofacial abnormalities,
developmental delay, and
distal limb defects

Maintain at the lowest
effective dose

None

Increased risk of gestational
diabetes, hypertension,
and fluid retention

Associated with increased
risk of cleft lip or palate if
used in first trimester;
increased risk of metabolic
syndrome in adulthood

May be used with
caution, if benefits
outweigh risks and
with continued
monitoring

Stop prior to
pregnancy, wait at
least 1 ovulation
cycle before planned
conception

Stop at least 3 mo prior
to planned
conception for both
men and women

May be used with
caution and
continued
monitoring

Stop at least 6 wk
before planned
conception

Men: Stop 3 mo prior
to planned
conception by a
treated
fatherWomen: May
be continued with
caution, if needed

Continue throughout
pregnancy and later

Management decision

None

Lactation

None

Impact on pregnancy/
delivery

None

Impact on fetus

Recommendations for use of maintenance medications for patients with MG regarding effects on fertility and pregnancy

Medication
recommendation

TABLE 1

4
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3.5.7 | Anti-calcineurins: Cyclosporine and
tacrolimus

Not recommended due
to lack of available
data

Management decision

GROVER AND SRIPATHI

The use of cyclosporine is associated with preterm labor and low birth
weight infants. No specific congenital malformations have been
reported. Tacrolimus use during pregnancy has been studied in transplant recipient population.37 Although it readily crosses the placenta,

Not recommended due
to limited data,
although no drug
detected in breast milk
per small case series.

Lactation

no major congenital malformations are reported.38 Preterm labor and
low birth weight infants are the commonly seen adverse effects of
exposure to tacrolimus prior to and during pregnancy. Transient neonatal hyperkalemia and renal impairment can occur, with spontaneous
resolution. Renal function and potassium levels should be monitored
in such neonates.

Rituximab

|

Rituximab is reserved for use in patients with severe myasthenic
weakness requiring frequent use of rescue treatments with either

No data available

Impact on pregnancy/
delivery

3.5.8

intravenous immunoglobulin (IVIg) or plasma exchange (PE). There is
limited data available regarding its use in pregnancy. It is generally
accepted that, due to the long half-life of the medication, pregnancy
should be avoided for 1 y after treatment, as hematological abnormalireported.39-41
Abbreviations: CNS, central nervous system; FDA, Food and Drug Administration; MG, myasthenia gravis.

No human data. Animal
studies show increased
rate of developmental
abnormalities and fetal loss
No human data. Animal
studies do not suggest any
effect on fertility
Not assigned
Eculizumab

Old FDA
pregnancy
classification
Medication
recommendation

TABLE 1

(Continued)

Effect on fertility

Impact on fetus

ties can be seen in the fetus. No malformations have been

3.5.9

|

Eculizumab

This is used in AChR antibody-positive MG patients with aggressive
disease requiring repeated use of IVIg or PE. There are no reports of
use of eculizumab in pregnant MG patients. Improved fetal and maternal survival has been reported in hemolytic-uremic syndrome or paroxysmal nocturnal hemoglobinuria patients treated with eculizumab
during pregnancy; however, this may not be extrapolated to the MG
patient population as these other diagnoses carry a high maternal
(8%–20%) and fetal (4%–9%) mortality.42,43 Animal studies show
increased fetal loss and developmental anomalies. The drug has been
shown to cross placenta and has the potential theoteric risk of causing
complement inhibtion in the newborn.43,44

3.6

|

Crisis during pregnancy

Worsening of MG symptoms and MG crisis can occur during the
course of pregnancy necessitating use of rescue treatments. There are
no data available regarding the incidence of MG crisis specifically
during pregnancy. A single review of 37 pregnancies in myasthenic
patients reported four crises (two during pregnancy and two occurring
in the postpartum period).45 In general, MG exacerbations occur
during pregnancy and the postpartum period in 19%–50% of women
with MG.3-5 The diagnostic evaluation for MG crisis is the same as in
non-pregnant patients—to evaluate for underlying infection and

6
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introduction of new medications, especially the use of magnesium for

3.8

|

Anesthetic management

pre-eclampsia/eclampsia. Recognition and timely treatment for exacerbation and crisis is important as they can impact the fetus nega-

As MG can affect the second stage of labor, adequate pain control

tively. Although there are no studies or reports about the effects of

may have a positive effect on muscle fatigue, and this potentially

MG crisis on the fetus, acute respiratory failure in the mother carries

could reduce cesarean section rates. No studies have evaluated the

a high risk of maternal morbidity and mortality.46,47 The treatment for

impact of pain control on the mode of delivery; however, it is plausible

MG crisis in a pregnant patient is the same as in a non-pregnant

that reducing muscle fatigue and stress of delivery could positively

patient, with stabilization of airway and cardiac parameters as well as

impact the outcome. Vaginal delivery with regional anesthesia is a pre-

consideration of either IVIg or PE. Both treatments, along with moni-

ferred method for well-controlled patients or those with mild-to-

toring for usual adverse events, can be safely performed during preg-

moderate disease severity. Of the regional anesthestics, epidural is

nancy. Monitoring for hypercoagulability, flu-like symptoms, fluid

preferred over spinal anesthesia.5,8,58,59 Epidural analgesia can be

overload, and renal impairment should be done when using IVIg as the

safely used during labor and delivery.58 Amide local anesthetics are

treatment option. With PE, monitoring for hypotension, infection, and

better with regard to safety as concomitant use of anticholinesterase

fluid shift is recommended. No increase in adverse effects is seen with

inhibitors does not impact their metabolism. Ester type anesthetic

48-51

either procedure during pregnancy.

agents, which are often used during labor, are rapidly hydrolyzed by
plasma cholinesterase, and in patients on cholinesterase inhibitors,
maternal and fetal toxicity may be enhanced.59 Ropivacaine has been

3.7

|

Labor and delivery

used more recently as it is less likely to produce a motor block.58
If cesarean section is warranted, epidural block may still be used.

For women who develop pre-eclampsia, monitoring of blood pressure

The presence of pre-existing respiratory impairment and the sup-

and appropriate treatment is very important. Monitoring for seizures

erimposed effect of high spinal motor block needs to be considered.

should be undertaken as well. Typically, in non-MG patients, IV

Patients with mild MG without respiratory compromise or purely ocu-

magnesium is the first line of treatment. Use of magnesium can result

lar MG may be best suited for spinal or epidural anesthesia. MG is not

in worsening of MG symptoms.52-55 Magnesium should be used

an indication for cesarean section by itself; however, the severity of

judiciously, with the clear understanding that it may precipitate crisis.

symptoms, especially the bulbar and respiratory muscle weakness,

Preferred treatment includes phenytoin or diazepam/lorazepam for

needs to be considered along with obstetrical indications. Patients

56,57

Control of hypertension can be achieved with

with severe bulbar and respiratory weakness should have cesarean

use of hydralazine. In refractory cases, labetalol may be used with

section performed under general anesthesia.59 Induction and mainte-

close monitoring of the MG.

nance of anesthesia with inhalational agents (isoflurane, sevoflurane)

seizure prophylaxis.

Vaginal delivery is recommended for women with MG. The first

or IV propofol and fentanyl should be considered.60-63 Use of neuro-

stage of active labor involves uterine smooth muscle contractions.

muscular blockers should be avoided unless absolutely necessary.

This stage is not affected by MG as smooth muscles have musca-

Sugammadex has been used successfully to reverse neuromuscular

rinic AChRs and are not affected by the MG antibodies. The second

blockade if neuromuscular blocking agents are used.64

stage of labor is characterized by a completely dilated cervix with
further descent of the fetal head, with it beginning to touch the pelvic floor. During this time, uterine contractions continue; however,
further movement of the baby in the birth canal is aided by volun-

4 | POSTPARTUM CARE FOR MOTHER
AND C HILD

tary contraction of the pelvic floor muscles. These muscles can get
fatigued if the labor is prolonged, requiring assistance in vaginal

4.1

|

Transient neonatal MG

delivery with vacuum suction extraction or forceps, or surgical intervention with a cesarean section. In a population-based cohort study

Weakness in sucking and swallowing resulting in feeding difficulty,

over 30 y, Hoff and colleagues reported increased use of elective

weak cry, and poor muscle tone as well as respiratory difficulty can be

cesarean section in patients with MG over time and reduced use of

seen in up to 20% of infants born to mothers with MG. This is thought

forceps and vacuum.7

to be caused by passive transfer of AChR or muscle specific kinase anti-

MG, in itself, is not an indication for performing a cesarean sec-

bodies through the placenta.65,66 Symptoms present within 3 days of

tion. It should be performed only for obstetrical indications. However,

birth and may last for a few months. Diagnosis is suggested by history

MG severity, including respiratory status, may need to be taken into

and confirmed by electrodiagnostic testing with abnormal RNS and

account when determining the mode of delivery.

detection of pathogenic antibodies in the neonate. AChR antibody epi-

Evaluation of the status of pulmonary function prior to delivery

tope specificity has been proposed as one of explanations for the rela-

should be considered. Careful monitoring of respiratory distress and

tive paucity of neonatal MG. A disproportionate ratio of antibodies

bulbar and muscular weakness during labor and puerperium is

against embryonic vs adult AChRs may influence the development of

warranted to expeditiously diagnose and treat an impeding

neonatal MG.67 Neither severity of disease in the mother nor antibody

myasthenic crisis.

titers correlate or predict the occurrence of neonatal MG. Thymectomy

7
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achieved. Lactation is contraindicated with concurrent use of cycloT A B L E 2 General guidelines in managing male and female MG
patients with child bearing potential

phosphamide. Cyclosporine is excreted in breast milk but is absorbed
in minimal amounts by infants after consumption. No nephrotoxicity

1. Assess disease activity and severity to determine the need for
continued immunosuppression.

has been reported in a case series.73 Methotrexate is excreted in very

2. Check for status of pregnancy, confirmed by laboratory testing.

methotrexate in breast milk is unknown; however, breast feeding is

3. Strongly recommend effective contraceptive measures when
initiating treatment with immunosuppressants, even in patients who
are not considering pregnancy.

not recommended until more data are available. Tacrolimus is

4. Strongly consider thymectomy, if clinically indicated.

rituximab is not recommended due to lack of data. In small case series,

5. Choose medications that would not impact fertility if the patient is
considering future pregnancy.

eculizumab was not detected in breast milk; however, no recommen-

6. Review treatment options if the patient is already on
immunosuppressive therapy and consider switching to medications
with no or minimal effect on fertility, all the while continuing
contraceptive measures.

women MG patients of child-bearing potential.

small amounts in breast milk. The effect on infants exposed to the

excreted in low quantity in breast milk. Per the available data, breast
feeding is not contraindicated in women on tacrolimus.74 Use of

dations can be made based on the case series.43,44,75
Table 2 lists general guidelines for managing both men and

7. Discontinue any medications with potential for teratogenicity prior
to pregnancy for at least the recommended time duration for that
particular agent.

DISCLOS URES

8. Counsel patients about regular follow up with the multidisciplinary
team during pregnancy for monitoring of the disease activity and
impact on the fetus.

ET HICAL PU BLICAT ION ST AT E ME NT

The authors have no conflict of interests to disclose.

We confirm that we have read the Journal's position on issues
involved in ethical publication and affirm that this report is consistent

9. Aggressively manage worsening disease activity with either intravenous
immunoglobulin or plasma exchange to reduce risk to the fetus.

with those guidelines.

10. Monitor the progression of labor and consider instrumentation
during the second stage of labor or escalate to cesarean section.

RE FE RE NCE S

11. Conduct neonatal monitoring for the development of transient
neonatal MG.

has a favorable influence in lowering the risk of neonatal MG in the
subsequent pregnancies.68 The symptoms respond well to the use of
cholinesterase inhibitors and resolve spontaneously.65,69
The transplacental influx of antibodies into fetal circulation may
result in decreased fetal movements, sometimes leading to congenital
arthrogryposis multiplex.70 There is no association of this rare complication to the severity of the MG in the mother. There is a higher risk of
recurrence of arthrogryposis multiplex in subsequent pregnancies and
in siblings.71

4.2

|

Lactation

Traditionally, use of immunosuppressive medications while breast
feeding has been felt to be associated with theoretical increased risk
of immunosuppression in the neonate. However, this may be more
dependent on the amount of excreted drug in the breast milk.
AZA metabolites are present in very low quantities in breast milk.
Infants ingesting such breast milk have not been reported to have any
adverse effects. Based on available data, use of AZA is not contraindicated during lactation.72 No data are available for excretion of
MMF in breast milk or its effect on infants. Given the lack of available
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